# RadNet, Inc.: overview

RDNT · Nasdaq · CIK 790526 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rdnt.md) · [Financials](/companies/rdnt/financials.md) · [Filings](/companies/rdnt/filings.md) · [Insiders](/companies/rdnt/insiders.md)

Latest reported revenue: [$622.7m](/filings/0001628280-26-055338.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-055338).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [461](/filings/0000790526-25-000008.md) | [477 d](/filings/0001628280-26-013337.md) | [471](/filings/0001628280-26-033607.md) | [498](/filings/0001628280-26-055338.md) | [523](/filings/0000790526-25-000008.md) | [548 d](/filings/0001628280-26-013337.md) | [576](/filings/0001628280-26-033607.md) | [623](/filings/0001628280-26-055338.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [7.4%](/filings/0000790526-25-000008.md) | [5.1% d](/filings/0001628280-26-013337.md) | [(5.1%)](/filings/0001628280-26-033607.md) | [6.2%](/filings/0001628280-26-055338.md) | [5.2%](/filings/0000790526-25-000008.md) | [5.1% d](/filings/0001628280-26-013337.md) | [(4.2%)](/filings/0001628280-26-033607.md) | [6.3%](/filings/0001628280-26-055338.md) |
| Net margin | % | [0.7%](/filings/0000790526-25-000008.md) | [1.1% d](/filings/0001628280-26-013337.md) | [(8.0%)](/filings/0001628280-26-033607.md) | [2.9%](/filings/0001628280-26-055338.md) | [1.0%](/filings/0000790526-25-000008.md) | [(0.1%) d](/filings/0001628280-26-013337.md) | [(5.8%)](/filings/0001628280-26-033607.md) | [1.2%](/filings/0001628280-26-055338.md) |
| Diluted EPS | $ per share | [0.04](/filings/0000790526-25-000008.md) | not reported | [(0.51)](/filings/0001628280-26-033607.md) | [0.19](/filings/0001628280-26-055338.md) | [0.07](/filings/0000790526-25-000008.md) | not reported | [(0.43)](/filings/0001628280-26-033607.md) | [0.10](/filings/0001628280-26-055338.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,315](/filings/0001628280-24-008035.md) | [1,430](/filings/0001628280-25-009481.md) | [1,617](/filings/0001628280-26-013337.md) | [1,830](/filings/0001628280-26-013337.md) | [2,040](/filings/0001628280-26-013337.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [6.3%](/filings/0001628280-24-008035.md) | [3.2%](/filings/0001628280-25-009481.md) | [6.1%](/filings/0001628280-26-013337.md) | [5.7%](/filings/0001628280-26-013337.md) | [3.0%](/filings/0001628280-26-013337.md) |
| Net margin | % | [1.9%](/filings/0001628280-24-008035.md) | [0.7%](/filings/0001628280-25-009481.md) | [0.2%](/filings/0001628280-26-013337.md) | [0.2%](/filings/0001628280-26-013337.md) | [(0.9%)](/filings/0001628280-26-013337.md) |
| Diluted EPS | $ per share | [0.46](/filings/0001628280-24-008035.md) | [0.17](/filings/0001628280-25-009481.md) | [0.05](/filings/0001628280-26-013337.md) | [0.04](/filings/0001628280-26-013337.md) | [(0.25)](/filings/0001628280-26-013337.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rdnt/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $675.8m | 10,957,808 |  | Added +922,074 |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $298.9m | 4,846,958 |  | Added +561,958 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $250.8m | 4,066,931 |  | Added +167,804 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $196.9m | 3,193,565 |  | Added +82,553 |
| [BECK MACK & OLIVER LLC](/funds/10742.md) | 2026-06-30 | $195.1m | 3,163,592 |  | Reduced −2,600 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $175.2m | 2,842,457 |  | Added +190,859 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $114.6m | 1,858,508 |  | Added +134,901 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $101.2m | 1,641,292 |  | Added +7,797 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $99.8m | 1,618,424 |  | Added +716,232 |
| [Clearbridge Investments, LLC](/funds/1348883.md) | 2026-06-30 | $95.4m | 1,546,652 |  | Added +268,112 |

## Recent filings

[All 1,116 filings](/companies/rdnt/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-26 | 16:11 ET | [8-K](/filings/0001683168-26-008094.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-26-008094 |
| 2026-08-14 | 16:17 ET | [8-K](/filings/0001683168-26-006479.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-26-006479 |
| 2026-08-10 | 17:06 ET | [10-Q](/filings/0001628280-26-055338.md) | Quarterly report, period 2026-06-30 | 0001628280-26-055338 |
| 2026-08-10 | 06:07 ET | [8-K](/filings/0001683168-26-006125.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001683168-26-006125 |
| 2026-06-10 | 17:23 ET | [8-K](/filings/0001683168-26-004716.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-26-004716 |
| 2026-06-04 | 21:08 ET | [8-K](/filings/0001683168-26-004522.md) | 5.07 Shareholder vote results | 0001683168-26-004522 |
| 2026-06-03 | 08:07 ET | [8-K](/filings/0001683168-26-004475.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-26-004475 |
| 2026-05-11 | 16:40 ET | [10-Q](/filings/0001628280-26-033607.md) | Quarterly report, period 2026-03-31 | 0001628280-26-033607 |
| 2026-05-11 | 07:24 ET | [8-K](/filings/0001683168-26-003624.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001683168-26-003624 |
| 2026-04-20 | 17:15 ET | [DEF 14A](/filings/0001683168-26-003086.md) | Proxy statement, period 2026-06-02 | 0001683168-26-003086 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-013337.md), filed Mar 2, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e0d4d5ff-e8ac-46a8-bdd4-886402216f0b)

## About the filer

- CIK: 790526
- Tickers: RDNT
- Exchange: Nasdaq
- SIC code: 8071 Services-Medical Laboratories
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:12 ET. No prices; not investment advice.